Your browser is no longer supported. Please, upgrade your browser.
Settings
BTAI [NASD]
BioXcel Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.12 Insider Own30.60% Shs Outstand24.96M Perf Week10.52%
Market Cap831.13M Forward P/E- EPS next Y-4.00 Insider Trans-18.22% Shs Float18.48M Perf Month-6.53%
Income-99.80M PEG- EPS next Q-1.05 Inst Own51.30% Short Float9.97% Perf Quarter23.57%
Sales- P/S- EPS this Y-87.20% Inst Trans1.32% Short Ratio6.97 Perf Half Y-15.52%
Book/sh10.71 P/B2.80 EPS next Y9.10% ROA-42.50% Target Price92.55 Perf Year-34.41%
Cash/sh9.84 P/C3.04 EPS next 5Y- ROE-45.30% 52W Range23.07 - 67.74 Perf YTD-35.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.04% Beta0.99
Dividend %- Quick Ratio22.20 Sales past 5Y- Gross Margin- 52W Low29.09% ATR1.73
Employees50 Current Ratio22.20 Sales Q/Q- Oper. Margin- RSI (14)50.54 Volatility4.90% 5.62%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.80% Profit Margin- Rel Volume0.55 Prev Close29.94
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume264.28K Price29.78
Recom1.60 SMA20-1.19% SMA502.81% SMA200-17.84% Volume72,878 Change-0.53%
Apr-09-21Initiated Berenberg Buy $75
Feb-01-21Initiated UBS Buy $99
Oct-30-20Initiated Goldman Buy $60
Sep-02-20Initiated Jefferies Buy $82
Aug-17-20Reiterated H.C. Wainwright Buy $200 → $175
Jul-08-20Reiterated H.C. Wainwright Buy $95 → $120
Jun-04-20Initiated Guggenheim Buy $101
Apr-01-20Initiated BofA/Merrill Buy $45
Feb-26-20Reiterated H.C. Wainwright Buy $30 → $95
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-12-19Initiated SunTrust Buy $24
Oct-20-21 10:00AM  
Oct-18-21 07:00AM  
Oct-14-21 11:39AM  
Sep-23-21 07:00AM  
Sep-17-21 06:05AM  
Sep-15-21 06:06PM  
Sep-12-21 06:05PM  
Sep-09-21 07:00AM  
Sep-03-21 07:21AM  
Aug-19-21 09:27AM  
Aug-10-21 07:00AM  
Jul-29-21 06:25AM  
Jul-28-21 07:00AM  
Jul-26-21 11:01AM  
Jul-19-21 07:30AM  
Jun-28-21 03:15PM  
Jun-25-21 02:33PM  
Jun-23-21 08:29AM  
04:11AM  
02:30AM  
Jun-22-21 04:01PM  
Jun-18-21 07:00AM  
May-26-21 07:00AM  
May-21-21 02:38AM  
May-19-21 07:00AM  
May-12-21 08:20AM  
May-11-21 07:00AM  
May-10-21 07:00AM  
06:45AM  
May-04-21 07:00AM  
May-03-21 07:00AM  
Apr-29-21 07:00AM  
Apr-26-21 07:00AM  
Apr-16-21 12:16PM  
Apr-15-21 08:00AM  
Apr-01-21 02:54PM  
06:26AM  
Mar-31-21 04:01PM  
Mar-16-21 06:07AM  
Mar-15-21 07:00AM  
Mar-11-21 08:19AM  
07:15AM  
07:00AM  
05:30AM  
Mar-04-21 07:00AM  
Mar-03-21 09:49AM  
07:00AM  
Mar-01-21 07:00AM  
Feb-25-21 11:46AM  
07:00AM  
05:30AM  
Feb-23-21 07:00AM  
Feb-17-21 10:00AM  
12:27AM  
Feb-12-21 07:00AM  
Feb-04-21 07:00AM  
Feb-01-21 04:54PM  
Jan-07-21 05:45AM  
Jan-05-21 07:00AM  
Dec-26-20 05:30PM  
Dec-17-20 07:00AM  
Dec-13-20 09:12AM  
Dec-12-20 10:42AM  
Dec-07-20 07:00AM  
Nov-16-20 09:06AM  
Nov-13-20 07:00AM  
Nov-12-20 07:00AM  
06:45AM  
Nov-11-20 07:00AM  
Nov-09-20 08:05AM  
Nov-05-20 07:00AM  
Oct-26-20 07:00AM  
Sep-25-20 11:25AM  
Sep-09-20 07:00AM  
Aug-21-20 10:20AM  
Aug-17-20 06:02AM  
Aug-14-20 12:34PM  
07:00AM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Jul-28-20 08:20PM  
Jul-27-20 04:21PM  
Jul-22-20 05:45AM  
Jul-20-20 04:33PM  
04:27PM  
11:44AM  
07:00AM  
Jul-09-20 07:00AM  
Jul-07-20 07:00AM  
Jul-05-20 09:21PM  
Jun-23-20 07:00AM  
Jun-17-20 09:43AM  
Jun-16-20 07:00AM  
Jun-15-20 04:05PM  
Jun-11-20 07:00AM  
Jun-04-20 09:42AM  
May-28-20 07:00AM  
May-15-20 05:45AM  
May-14-20 07:00AM  
May-12-20 10:31PM  
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nandabalan KrishnanDirectorJun 25Sale30.83473,25014,589,4938,546,750Jun 29 05:23 PM
Mehta VimalCEO, President and SecretaryJun 25Sale30.83473,25014,589,4938,546,750Jun 29 05:23 PM
BioXcel LLC10% OwnerJun 25Sale30.83473,25014,589,4938,546,750Jun 29 05:22 PM
BioXcel Holdings, Inc.10% OwnerJun 25Sale30.83473,25014,589,4938,546,750Jun 29 05:21 PM
Yocca FrankChief Scientific OfficerMar 15Sale48.5015,000727,57358,397Mar 17 05:00 PM
O'Neill VincentChief Medical OfficerFeb 17Option Exercise4.6525,000116,15025,000Feb 19 07:35 PM
O'Neill VincentChief Medical OfficerFeb 17Sale55.5825,0001,389,4590Feb 19 07:35 PM
Yocca FrankChief Scientific OfficerFeb 16Sale57.6815,000865,15373,397Feb 18 04:56 PM
Steinhart Richard IChief Financial OfficerFeb 01Option Exercise5.553,75020,8125,250Feb 03 04:15 PM
Steinhart Richard IChief Financial OfficerFeb 01Sale48.153,750180,5621,500Feb 03 04:15 PM
Yocca FrankChief Scientific OfficerJan 25Option Exercise0.4115,0006,150103,397Jan 27 04:25 PM
Yocca FrankChief Scientific OfficerJan 25Sale48.3915,000725,81488,397Jan 27 04:25 PM
O'Neill VincentChief Medical OfficerJan 19Option Exercise0.4125,00010,25025,000Jan 21 04:15 PM
O'Neill VincentChief Medical OfficerJan 19Sale49.4725,0001,236,7190Jan 21 04:15 PM
O'Neill VincentChief Medical OfficerDec 28Option Exercise0.4125,00010,25025,000Dec 30 04:15 PM
O'Neill VincentChief Medical OfficerDec 28Sale51.4525,0001,286,1570Dec 30 04:15 PM